97 related articles for article (PubMed ID: 19715943)
1. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation.
Fraile P; García-Cosmes P; Martín P; García-Bernalt V; Tabernero JM
Transplant Proc; 2009; 41(6):2433-4. PubMed ID: 19715943
[TBL] [Abstract][Full Text] [Related]
2. Non-lymphoid cancer after liver transplantation.
Frezza EE; Fung JJ; van Thiel DH
Hepatogastroenterology; 1997; 44(16):1172-81. PubMed ID: 9261620
[TBL] [Abstract][Full Text] [Related]
3. De novo tumors after liver transplantation: a single-institution experience.
Sanchez EQ; Marubashi S; Jung G; Levy MF; Goldstein RM; Molmenti EP; Fasola CG; Gonwa TA; Jennings LW; Brooks BK; Klintmalm GB
Liver Transpl; 2002 Mar; 8(3):285-91. PubMed ID: 11910575
[TBL] [Abstract][Full Text] [Related]
4. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
5. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors.
Kelly DM; Emre S; Guy SR; Miller CM; Schwartz ME; Sheiner PA
Cancer; 1998 Sep; 83(6):1237-43. PubMed ID: 9740091
[TBL] [Abstract][Full Text] [Related]
6. Cancers after renal transplantation: multicenter experience.
Harzallah K; Abderrahim E; Chareffedine K; Yeich S; Belhadj R; Skhiri H; Younsi F; Abdallah TB; Abdelletif A; Hachicha J; Hmida J; El May M; Khedr A; Manaa J
Saudi J Kidney Dis Transpl; 2008 Sep; 19(5):825-30. PubMed ID: 18711309
[TBL] [Abstract][Full Text] [Related]
7. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for malignancy in Japanese renal transplant recipients.
Imao T; Ichimaru N; Takahara S; Kokado Y; Okumi M; Imamura R; Namba Y; Isaka Y; Nonomura N; Okuyama A
Cancer; 2007 May; 109(10):2109-15. PubMed ID: 17407138
[TBL] [Abstract][Full Text] [Related]
9. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
10. Cancer incidence and survival in kidney transplant patients.
Navarro MD; López-Andréu M; Rodríguez-Benot A; Agüera ML; Del Castillo D; Aljama P
Transplant Proc; 2008 Nov; 40(9):2936-40. PubMed ID: 19010153
[TBL] [Abstract][Full Text] [Related]
11. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
[TBL] [Abstract][Full Text] [Related]
12. Short-term outcome of chronic immunosuppression on the development of breast lesions in premenopausal heart and lung transplant patients.
Campbell A; Moazami N; Ditkoff BA; Kurtz E; Estabrook A; Schnabel F
J Surg Res; 1998 Jul; 78(1):27-30. PubMed ID: 9733613
[TBL] [Abstract][Full Text] [Related]
13. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
[TBL] [Abstract][Full Text] [Related]
14. [Incidence of tumors in renal transplant patients. Is there a changing tumor pattern in these patients?].
Hermida Gutiérrez JF; Moreno Sierra J; Blázquez Izquierdo J; Gómez Vegas A; Silmi Moyano A; Prats Sánchez D; Fernández Pérez C; Resel Estévez L
Arch Esp Urol; 1998 Sep; 51(7):683-91. PubMed ID: 9807894
[TBL] [Abstract][Full Text] [Related]
15. Development of lymphoproliferative disease after liver transplantation.
Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
[TBL] [Abstract][Full Text] [Related]
16. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
17. Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy.
Singh SK; Gupta AK; Jha V; Kohli HS; Gupta KL; Minz M; Sakhuja V
Transplant Proc; 2006 Sep; 38(7):2088-9. PubMed ID: 16980008
[TBL] [Abstract][Full Text] [Related]
18. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
[No Abstract] [Full Text] [Related]
19. Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases.
Zhou M; Zhu Y; Wang L; Wang Y; Fu S; Min Z
Clin Transpl; 2006; ():395-8. PubMed ID: 18365395
[TBL] [Abstract][Full Text] [Related]
20. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
